8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 17, 2021

DANIMER SCIENTIFIC, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-39280	84-1924518
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
140 Industrial Boulevard
Bainbridge, Georgia		39817
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 229 243-7075

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common stock, $0.0001 par value per share	DNMR	The New York Stock Exchange
Warrants to purchase one share of Common Stock	DNMR WS	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 17, 2021, Danimer Scientific, Inc. (“Danimer” or the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2021. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The press release contains the following non-GAAP measures: Adjusted EBITDA”, “Adjusted EBITDAR” and “Adjusted Gross Profit”. The Company believes that each of Adjusted EBITDA, Adjusted EBITDAR and Adjusted Gross Profit is useful to investors in evaluating the Company’s performance because each measure considers the performance of Danimer’s operations, excluding decisions made with respect to capital investment, financing and other non-recurring charges. Danimer believes these non-GAAP metrics offer additional financial information that, when coupled with the GAAP results and the reconciliation to GAAP results, provides a more complete understanding of its results of operations and the factors and trends affecting its business. The non-GAAP measures are reconciled to comparable GAAP financial measures within the press release. The Company cautions that non-GAAP measures should be considered in addition to, but not as a substitute for, the Company’s reported GAAP results. Additionally, the Company notes that there can be no assurance that the above referenced non-GAAP financial measures are comparable to similarly titled financial measures used by other publicly traded companies

The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing of Danimer, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing.

Item 9.01 Financial Statements and Exhibits.

d)  Exhibits.

Exhibit No.	Description
99.1	Press Release, dated May 17, 2021, reporting financial results for the quarter ended March 31, 2021 (furnished only).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Danimer Scientific, Inc
Date:	May 17, 2021	By:	/s/ John A. Dowdy, III
			John A. Dowdy, III Chief Financial Officer

EX-99.1

Exhibit 99.1

Danimer Scientific, a Next Generation Bioplastics Company, Announces First Quarter 2021 Results

BAINBRIDGE, Ga.--(BUSINESS WIRE)-- Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today its financial results for the quarter ended March 31, 2021.

“Danimer Scientific remains at the forefront of the bioplastics industry as the premier supplier of PHA biopolymers to blue-chip multinational corporations that are committed to reducing single-use plastic waste,” commented Stephen E. Croskrey, Chief Executive Officer of Danimer. “In the first quarter 2021, we continued to make progress on our facility expansions, customer application developments and other investments in our operational infrastructure in order to serve the current and long-term demand for our next generation Nodax® technology. We are excited to have announced a multi-year partnership with Mars Wrigley to develop innovative compostable packaging. Looking ahead, we continue to expect that our expansion of production capacity, contracted revenue streams and future efficiencies will collectively fuel the path forward to fulfilling our goal of profitably transforming the bioplastics industry on a global scale.”

First Quarter 2021 Financial Highlights

Revenues increased 24% to $13.2 million, compared to the first quarter of 2020, driven by stronger demand and additional PHA production at the Company’s Winchester, Kentucky Phase 1 facility brought on line in 2020. PHA-based products represented 29% of total revenue compared to 2% in the first quarter of 2020.

Gross profit of $1.5 million, compared to $3.2 million in the first quarter of 2020. Adjusted gross profit1 was $3.9 million, compared to $4.1 million in the first quarter of 2020. Adjusted gross margin was 29.2%, compared to 38.6% in the first quarter of 2020, primarily attributable to product mix. In both periods, the average cost per pound of PHA-based products sold was significantly higher than PLA-based products sold and we had only limited PHA manufacturing activities in early 2020 at the Kentucky facility. The average cost per unit sold is expected to improve as PHA production continues to increase and efficiency measures are implemented. Adjusted gross profit excludes stock-based compensation, depreciation and amortization, as well as rent expense.

Net loss of $94.7 million included an $80.7 million loss related to the revaluation of the Company’s private warrants.

Adjusted EBITDA1 loss of $2.3 million, compared to break even in the first quarter of 2020, primarily due to higher operating expenses attributable to an increase in

headcount and salaries to support R&D efforts and future expansion plans. The first quarter 2021 also included public company expenses of approximately $1.0 million.

Adjusted EBITDAR1, which additionally excludes rent expense primarily associated with the Company’s Kentucky facility and Georgia production operations, was a loss of $1.6 million, compared to income of $0.7 million in the prior year.

(1) An explanation of non-GAAP measures disclosed in this release and a reconciliation of these non-GAAP results to comparable GAAP measures are included in the “Non-GAAP Financial Measures” section of the release.

Facility Network Expansion

Market demand remains robust for Danimer’s signature polymer, Nodax® PHA (polyhydroxyalkanoate), a 100% biodegradable, renewable, and sustainable plastic produced using plant-based oils as a primary feedstock. Expanding commitments from blue chip multinational consumer packaging customers support Danimer’s announced nameplate capacity additions to produce and deliver up to an estimated 315 million pounds of finished PHA product per year.

The Winchester, Kentucky facility is currently producing and shipping PHA at a commercial scale. In the first quarter 2021, neat PHA production volume at the facility was at approximately 50% of capacity. As previously disclosed, during the second quarter of 2021, the Company is scheduled to temporarily take the facility offline to implement several debottlenecking initiatives, with the objective to accelerate the facility’s scaling up of production to 100% of existing capacity by the end of 2021.

Phase II of the Kentucky plant expansion is in process to increase total capacity to 65 million finished pounds annually. Construction is underway with the physical foundations built for the fermentation chiller, downstream processing and extrusion facilities that form the integrated production process for PHA-based resins. The Company continues to expect its Phase II expansion to come online in the second quarter of 2022.

In March 2021, the Company together with the State of Georgia announced the Company’s new state-of-the-art greenfield facility will be located in Bainbridge, GA. With anticipated capacity of 250 million finished pounds of PHA products annually to keep up with robust PHA demand, the facility is in the pre-construction engineering stage and is on track for an expected groundbreaking to take place in the first quarter of 2022. The greenfield capacity will come on line in two phases, with an initial three fermenters expected to be operational in mid-2023 and the second set of three fermenters anticipated to come on line in early 2024. Based on the current demand pipeline, the Company forecasts that capacity at the greenfield facility will be sold out.

Liquidity and Capital Resources

At March 31, 2021, the Company had total debt outstanding of $31.7 million and cash of $312.9 million, including transaction net proceeds resulting from the merger between Danimer and Live Oak completed in December 2020. In January 2021, the Company voluntarily paid off and terminated its 2019 Term Loan with a principal amount of $27 million, further delevering its balance sheet and providing additional flexibility to pursue more competitively priced financing in the future.

In April 2021, the Company entered into a new 5-year $20.0 million variable interest rate asset-based lending arrangement and a $1.0 million capital expenditure line with customary terms and conditions. The facility provides additional flexibility to invest in initiatives as the Company grows.

In May 2021, the Company commenced the process to redeem all of its outstanding publicly-traded warrants to purchase shares of its common stock at an exercise price of $11.50 per share. The transaction is expected to be completed in June 2021, simplifying the Company’s capital structure and providing additional funding to invest in the ongoing expansion of the business.

Financial Statement Update on Non-Cash Impact Related to Warrants

On May 7, 2021, the Company filed a Current Report on Form 8-K and issued a press release in response to the public statement released by the staff of the Securities and Exchange Commission on April 12, 2021 regarding accounting and reporting considerations that are broadly applicable to warrants issued by special purpose acquisition companies ("SPACs"). Similar to other SPACs, the Company had previously classified its private warrants, which were originally issued by the SPAC that the Company merged with in 2020, as equity. However, after evaluating the SEC statement and consulting with its advisors, the Company concluded that certain of its warrants should be classified as liabilities in the Company's consolidated financial statements. The Company has restated its audited consolidated financial statements for the year ended December 31, 2020 to classify the Company’s private warrants as a liability instead of as equity and to reflect the change in the fair value of such liability in each period as a non-cash charge or gain in the consolidated statements of operations.

This restatement had no impact on Danimer’s current or historical reported cash or cash equivalents, revenues, loss from operations, or cash flows from operating, investing, or financing activities. This change will not affect GAAP revenues, loss from operations, long-term debt or cash flows from operating, investing, or financing activities, or the non-GAAP measures Adjusted EBITDA, Free Cash Flow or Adjusted Free Cash Flow, or its ongoing operations or future growth plans. The restatement resulted in the Company recording a liability of $82.9 million as of December 31, 2020, and an unrealized non-operating gain of $3.7 million reflecting the change in the fair value of the private warrant liability between the closing of the SPAC merger transaction on

December 29th and the end of the fiscal year on December 31, 2020. During the first quarter of 2021, the liability related to private warrants increased to $149.6 million, resulting in a loss on private warrants revaluation of $80.7 million for the three-month period. Since the private warrants are being accounted for as liabilities, the change in the fair value of such liability is recognized as a non-cash charge or gain in the consolidated statements of operations. The Company does not expect the change to have any significant impact on operational performance or debt covenant compliance in future periods. Additional information on the restatement can be found in the Company’s 10-K/A.

Business Outlook

The Company reiterates its expectation for increased PHA output after debottlenecking initiatives scheduled to be implemented during the second quarter of 2021, providing for increased product availability upon completion. The Company continues to expect Adjusted EBITDA and cash flow from operations to benefit in 2021 from these improvements with a partial offset from accelerated investments in headcount and technology to build out the operational platform and infrastructure needed to support our transformational capacity expansion and sales growth. The Company now expects full year capital expenditures to be in the range of $120 million to $145 million, with the increase from the prior range mainly attributable to higher costs for construction materials while the Company continues to evaluate value engineering opportunities.

Webcast and Conference Call

The Company will host a webcast and conference call on Monday, May 17, 2021, at 5:00 p.m. Eastern time to review first quarter 2021 results, discuss recent events and conduct a question-and-answer session. The live webcast will be available at www.danimerscientific.com in the Investor Relations section. The conference call will also be accessible by dialing 1-855-327-6837 (Domestic) and 1-631-891-4304 (International). A replay of the webcast will be available on the Company’s website.

About Danimer

Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer’s technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, fibers, filaments, films and injection-molded articles, among others. Danimer now holds more than 150 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, visit www.DanimerScientific.com.

Forward-Looking Statements

Please note that in this press release we may use words such as “appears,” “anticipates,” “believes,” “plans,” “expects,” “intends,” “future,” and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are made based on Management’s expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. The Company cautions that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to, the overall level of consumer demand on its products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company's customers; the Company's ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to its products; the Company’s exposure to product liability or product warranty claims and other loss contingencies; disruptions and other impacts to the Company’s business, as a result of the COVID-19 global pandemic and government actions and restrictive measures implemented in response; stability of the Company’s manufacturing facilities and suppliers, as well as consumer demand for its products, in light of disease epidemics and health-related concerns such as the COVID-19 global pandemic; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company's ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, its information systems; the ability of its information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; its ability to properly maintain, protect, repair or upgrade its information technology systems or information security systems, or problems with its transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; its ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks . More information on potential factors that could affect the Company's financial results is included from time to time in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K/A, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking

statements included in this press release are based upon information available to the Company as of the date of this press release, and speak only as of the date hereof. The Company assumes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.

Danimer Scientific, Inc. Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share data)	March 31,		December 31,
	2021		2020
Assets
Current assets
Cash and cash equivalents	$	312,910	$	377,581
Accounts receivable, net		10,114		6,605
Inventories		16,846		13,642
Prepaid expenses and other current assets		4,565		3,089
Contract assets		1,397		1,466
Total current assets		345,832		402,383
Property, plant and equipment, net		129,577		106,795
Patents, net		1,764		1,801
Right-of-use assets		19,329		19,387
Leverage loans receivable		13,408		13,408
Restricted cash		2,320		2,316
Other assets		73		111
Total assets	$	512,303	$	546,201
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	10,797	$	10,610
Accrued liabilities		7,652		9,220

Unearned revenue and contract liabilities		2,336			2,455
Current portion of lease liability		3,058			3,000
Current portion of long-term debt, net		345			25,201
Total current liabilities		24,188			50,486
Private warrants liability		149,635			82,860
Long-term lease liability, net		23,952			24,175
Long-term debt, net		31,316			31,386
Other long-term liabilities		938			1,250
Total liabilities		230,029			190,157
Commitments and Contingencies
Stockholders' equity
Common stock, $0.0001 par value; 200,000,000 shares authorized: 85,339,145 and 84,535,640 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively		9			8
Additional paid-in-capital		435,782			414,819
Accumulated deficit		(153,517	)		(58,783	)
Total stockholders’ equity		282,274			356,044
Total liabilities and stockholders’ equity	$	512,303		$	546,201

Danimer Scientific, Inc. Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share data)	Three Months Ended March 31,

	2021			2020
Revenue:
Products	$	11,024		$	9,179
Services		2,157			1,419
Total revenue		13,181			10,598
Costs and expenses:
Cost of revenue		11,725			7,429
Selling, general and administrative		10,120			2,980
Research and development		2,619			1,247
Total costs and expenses		24,464			11,656
Loss from operations		(11,283	)		(1,058	)
Nonoperating income (expense):
Loss on remeasurement of private warrants		(80,697	)		-
Interest expense, net		(200	)		(713	)
Loss on debt extinguishment		(2,604	)		-
Other income, net		50			90
Total nonoperating expenses		(83,451	)		(623	)
Loss before income taxes		(94,734	)		(1,681	)
Income tax expense		-			-
Net loss	$	(94,734	)	$	(1,681	)
Net loss per share:
Basic and diluted net loss per share	$	(1.12	)	$	(0.06	)
Weighted average number of shares used to compute basic and diluted net loss per share (March 31, 2020 balance as retroactively restated for Business Combination):		84,708,137			27,761,717

Danimer Scientific, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited)
	Three Months Ended
(in thousands)	March 31,
	2021			2020
Cash flows from operating activities
Net loss	$	(94,734	)	$	(1,681	)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on remeasurement of private warrants		80,697			-
Stock-based compensation		6,665			148
Depreciation and amortization		2,100			870
Loss on writeoff of deferred loan costs		1,900			-
Amortization of debt issuance costs and debt discounts		82			233
Amortization of right-of-use assets and lease liability		41			128
Other		38			89
Changes in operating assets and liabilities
Accounts receivable, net		(3,509	)		(1,736	)
Inventories		(3,204	)		(3,133	)
Prepaid expenses and other current assets		(1,498	)		(42	)
Other assets		125			(191	)
Accounts payable		(669	)		268
Accrued and other long-term liabilities		(2,123	)		(156	)
Unearned revenue and contract liabilities		(119	)		(412	)
Net cash used in operating activities		(14,208	)		(5,615	)
Cash flows from investing activities
Purchases of property, plant and equipment		(23,893	)		(15,340	)

Net cash used in investing activities		(23,893	)		(15,340	)
Cash flows from financing activities
Principal payments on long-term debt		(27,037	)		(404	)
Proceeds from exercise of stock options		1,191			-
Capital issuance costs
Proceeds from long-term debt		120			2,435
Payments for debt issuance costs		(25	)		(27	)
Proceeds from NMTC financing		-			91
Proceeds from issuance of common stock, net of issuance costs		(815	)		24,916
Net cash (used in) provided by financing activities		(26,566	)		27,011
Net (decrease) increase in cash and cash equivalents and restricted cash		(64,667	)		6,056
Cash and cash equivalents and restricted cash-beginning of period		379,897			6,261
Cash and cash equivalents and restricted cash-end of period	$	315,230		$	12,317
Supplemental cash flow information
Cash paid for interest, net of interest capitalized	$	130		$	413
Cash paid for income taxes	$	-		$	-
Cash paid for operating leases	$	798		$	631
Supplemental non-cash disclosure
Noncash capital expenditures	$	951		$	(2,777	)

Non-GAAP Financial Measures

This press release includes the non-GAAP financial measures “Adjusted EBITDA”, “Adjusted EBITDAR” and “Adjusted Gross Profit”. Danimer management views these metrics as a useful way to look at the performance of its operations between periods

and to exclude decisions on capital investment and financing that might otherwise impact the review of profitability of the business based on present market conditions.

Adjusted EBITDA is defined as net income or loss plus net interest expense, income taxes, depreciation and amortization, as adjusted to add back certain charges or gains that Danimer may record each period such as remeasurement of private warrants, stock-compensation expense, as well as non-recurring charges such as (i) asset disposal gains or losses as well as other significant gains or losses such as debt extinguishments; (ii) legal settlements; or (iii) other discrete non-recurring items. Danimer believes these items are not considered an indicator of ongoing performance. Adjusted EBITDA is not a measure of performance defined in accordance with GAAP. The measure is used as a supplement to GAAP results in evaluating certain aspects of Danimer’s business, as described below.

Adjusted EBITDAR is defined as Adjusted EBITDA plus rent expense.

Adjusted Gross Profit is defined as Gross Profit plus depreciation, stock-based compensation and rent expense.

Danimer believes that each of Adjusted EBITDA, Adjusted EBITDAR and Adjusted Gross Profit is useful to investors in evaluating the Company’s performance because each measure considers the performance of the Company’s operations, excluding decisions made with respect to capital investment, financing and other non-recurring charges as outlined in the preceding paragraph. Danimer believes these non-GAAP metrics offers additional financial information that, when coupled with the GAAP results and the reconciliation to GAAP results, provides a more complete understanding of its results of operations and the factors and trends affecting its business.

Adjusted EBITDA, Adjusted EBITDAR and Adjusted Gross Profit should not be considered as an alternative to net income or loss as an indicator of its performance or as alternatives to any other measure prescribed by GAAP as there are limitations to using such non-GAAP measures. Although Danimer believes that Adjusted EBITDA, Adjusted EBITDAR and Adjusted Gross Profit may enhance an evaluation of its operating performance based on recent revenue generation and product/overhead cost control because it excludes the impact of prior decisions made about capital investment, financing and other expenses, (i) other companies in Danimer’s industry may define Adjusted EBITDA, Adjusted EBITDAR and Adjusted Gross Profit differently than Danimer does and, as a result, they may not be comparable to similarly titled measures used by other companies in its industry, and (ii) Adjusted EBITDA, Adjusted EBITDAR and Adjusted Gross Profit exclude certain financial information that some may consider important in evaluating Danimer’s performance.

Danimer compensates for these limitations by providing disclosure of the differences between Adjusted EBITDA, Adjusted EBITDAR and Adjusted Gross Profit and GAAP

results, including providing a reconciliation to GAAP results, to enable investors to perform their own analysis of Danimer’s operating results.

Danimer Scientific, Inc. Reconciliation of Adjusted EBITDAR and Adjusted EBITDA to Net Loss (Unaudited)
	Three Months Ended March 31,
	2021			2020
Net Loss	$	(94,734	)	$	(1,681	)
Interest expense, net		200			713
Income tax expense		-			-
Deprecation and amortization		2,100			870
Loss on remeasurement of private warrants		80,697			-
Stock-based compensation		6,665			148
Loss on debt extinguishment		2,604			-
Public company transition costs		207			-
Other income, net		(50	)		(90	)
Adjusted EBITDA	$	(2,311	)	$	(40	)
Rent		725			786
Adjusted EBITDAR	$	(1,585	)	$	746
Reconciliation of Adjusted Gross Profit to Gross Profit (Unaudited)
	Three Months Ended March 31,
	2021			2020
Total Revenue	$	13,181		$	10,598
Cost of Revenue		11,725			7,429
Gross Profit		1,456			3,169
Depreciation		1,839			683

Rent		530		216
Stock-based compensation		26		25
Adjusted Gross Profit	$	3,851	$	4,094

Contacts

Investorsir@danimer.com
Phone: 229-220-1103

Media
Anthony Popiel
apopiel@daltonagency.com
Phone: 310-787-4807

Source: Danimer Scientific, Inc

XML

Document And Entity Information	May 17, 2021
Document Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 17, 2021
Entity Registrant Name	DANIMER SCIENTIFIC, INC.
Entity Central Index Key	0001779020
Entity Emerging Growth Company	true
Entity File Number	001-39280
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-1924518
Entity Address, Address Line One	140 Industrial Boulevard
Entity Address, City or Town	Bainbridge
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	39817
City Area Code	229
Local Phone Number	243-7075
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Ex Transition Period	false
Common Class A [Member]
Document Information [Line Items]
Title of 12(b) Security	Class A Common stock, $0.0001 par value per share
Trading Symbol	DNMR
Security Exchange Name	NYSE
Warrant to Purchase [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase one share of Common Stock
Trading Symbol	DNMR WS
Security Exchange Name	NYSE